The Princeton IV consensus recommendations for the management of erectile dysfunction and cardiovascular disease Guidelines
| Authors: | Köhler, T. S.; Kloner, R. A.; Rosen, R. C.; Burnett, A. L.; Blaha, M. J.; Ganz, P.; Goldstein, I.; Kim, N. N.; Lue, T.; McVary, K. T.; Mulhall, J. P.; Parish, S. J.; Sadeghi-Nejad, H.; Sadovsky, R.; Sharlip, I. D.; Miner, M. |
| Title: | The Princeton IV consensus recommendations for the management of erectile dysfunction and cardiovascular disease |
| Abstract: | The Princeton Consensus (Expert Panel) Conference is a multispecialty collaborative symposium dedicated to optimizing sexual function and preserving cardiovascular health. The Fourth Princeton Consensus Conference was convened on March 10-11, 2023, at the Huntington Medical Research Institutes in Pasadena, California. Princeton panels I to III addressed the clinical management of men with erectile dysfunction (ED) who also had cardiovascular disease. Thirteen years since Princeton III, Princeton IV builds on previous foundations in several key areas. Mounting evidence supports the need for providers to treat men with ED as being at risk for cardiac events until proven otherwise. Algorithms for the diagnosis and treatment of ED are updated with new recommendations for coronary artery calcium scoring for advanced cardiovascular risk stratification. Optimization of oral phosphodiesterase type 5 inhibitors in the treatment of men with ED and cardiovascular disease is thoroughly explored, including recent evidence of potential cardioprotective effects of these drugs. © 2024 Mayo Foundation for Medical Education and Research |
| Keywords: | mortality; hypertension; consensus; apoptosis; computer assisted tomography; sexual satisfaction; exercise; anticoagulant therapy; deep vein thrombosis; risk factor; risk assessment; prostate cancer; lung embolism; coronary artery bypass graft; hypotension; depression; body mass; training; prostatectomy; cardiovascular disease; cardiovascular risk; heart failure; atherosclerosis; papaverine; cognition; high density lipoprotein cholesterol; low density lipoprotein cholesterol; dyslipidemia; metabolic syndrome x; systolic blood pressure; oxidative stress; anxiety; physical activity; body composition; insulin sensitivity; testosterone blood level; echocardiography; lifestyle modification; erectile dysfunction; atrial fibrillation; coronary artery disease; sexual function; heart protection; health care delivery; hyperlipidemia; phosphodiesterase v inhibitor; sildenafil; tadalafil; vardenafil; hemodynamics; treadmill exercise; sexual behavior; computed tomographic angiography; lifestyle; stress echocardiography; venous thromboembolism; randomized controlled trial (topic); international index of erectile function; reperfusion injury; symposium; pulmonary hypertension; heart rate; premature ejaculation; priapism; sexual health; energy expenditure; valsartan; coronary artery blood flow; tachyphylaxis; glycemic control; sex therapy; phosphodiesterase v; data mining; arterial wall thickness; peripheral arterial disease; human; male; article; heart muscle revascularization; sacubitril; sacubitril plus valsartan; coronary atherosclerosis; six minute walk test; coronary artery calcium score; riociguat; heart outflow tract obstruction; performance anxiety |
| Journal Title: | Mayo Clinic Proceedings |
| Volume: | 99 |
| Issue: | 9 |
| ISSN: | 0025-6196 |
| Publisher: | Mayo Clinic Proceedings |
| Date Published: | 2024-09-01 |
| Start Page: | 1500 |
| End Page: | 1517 |
| Language: | English |
| DOI: | 10.1016/j.mayocp.2024.06.002 |
| PUBMED: | 39115509 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
